Journal profile · Multiple
Hepatoma Research
ISSN 2394-5079 · eISSN 2454-2520 · OAE Publishing Inc.
Hepatoma Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.8 (journal website); fully open access; APC about USD 2,600; review about 10 days (submission to first decision, publisher); 29 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Hepatoma Research is published by OAE Publishing Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Liver Disease Diagnosis and Treatment, Hepatocellular Carcinoma Treatment and Prognosis and Hepatitis C virus research, together about 56% of its articles. Its main subfields are Hepatology. (generated from OpenAlex topic counts and CAS ranking data)
Hepatoma Research focuses on research related to liver cancer, biliary tract cancers, and liver diseases. It covers topics such as their occurrence, development, diagnosis, prevention, and treatment. The journal publishes high-quality basic, translational, clinical, and population-based studies across the continuum of liver oncology and related disciplines. The scope of the journal includes the following areas: • Liver cancer (primary focus)Liver cancer, with a focus on hepatocellular carcinoma, including etiologically and biologically defined disease subtypes associated with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, metabolic dysfunction, inflammation, immune dysregulation, and viral evolution.Development and validation of diagnostic, prognostic, and predictive biomarkers for liver cancer, including molecular, imaging, and multi-parameter biomarkers relevant to early detection, risk stratification, and assessment of treatment response.Therapeutic strategies and clinical management of liver cancer, including basic and clinical research on animal models, liver transplantation, surgical and interventional therapies, molecular targeted therapy, immunotherapy, combination treatment strategies, treatment-related drugs and complications, and the clinical translation of emerging laboratory discoveries. • Biliary tract cancersMolecular and cellular mechanisms underlying biliary tract cancers, particularly intrahepatic cholangiocarcinoma, with relevance to liver oncology.Diagnostic, prognostic, and predictive biomarkers for biliary tract cancers.Clinical management and therapeutic approaches for biliary tract cancers, including surgical, interventional, systemic, and translational treatment strategies. • Chronic liver diseases associated with liver cancer riskChronic liver diseases that are associated with an increased risk of liver cancer include chronic viral hepatitis, metabolic dysfunction–associated steatotic liver disease, alcohol-related liver disease, liver fibrosis, cirrhosis, and immune-mediated liver diseases.Risk stratification, surveillance strategies, and preventive interventions for liver cancer in patients with high-risk liver diseases.Translational studies linking chronic liver disease biology to hepatocarcinogenesis and early malignant transformation. • Epidemiology and public healthDescriptive epidemiological studies of liver cancer and biliary tract cancers, including an analysis of time trends in incidence, mortality, survi
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief Guangwen CaoPublisher website
Editorial board by country: 40 in mainland China (about 40%); most named Mainland China 40, Italy 19, United States 6, Germany 4, Hong Kong, China 3 (99 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Liver Disease Diagnosis and TreatmentMedicine25.1%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine24.5%
- Hepatitis C virus researchMedicine6.4%
- Cholangiocarcinoma and Gallbladder Cancer StudiesMedicine5.8%
- Hepatitis B Virus StudiesMedicine5.4%
- Liver Disease and TransplantationMedicine3.6%
- Liver physiology and pathologyMedicine3.2%
- Organ Transplantation Techniques and OutcomesMedicine2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Gastroenterology & Hepatology | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Gastroenterology & Hepatology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 1.8Publisher website ·
- CiteScore 2026-06
- 3LetPub ·
- CiteScore (publisher)
- 3Publisher website ·
- SJR 2026-06
- 0.46LetPub ·
- SNIP 2026-06
- 0.35LetPub ·
- h-index
- 26OpenAlex ·
- i10-index
- 121OpenAlex ·
- 2-year mean citedness
- 1.61OpenAlex ·
- Self-citation rate
- 11.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 28LetPub ·
- Articles per year (publisher) 2026
- 2,026Publisher website ·
- Downloads per year (publisher)
- 1,024,116Publisher website ·
Articles by year OpenAlex count · 638 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 55 | 55 | 16 |
| 2025 | 29 | 29 | 61 |
| 2024 | 53 | 53 | 143 |
| 2023 | 53 | 53 | 147 |
| 2022 | 41 | 41 | 282 |
| 2021 | 78 | 78 | 527 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Desk decision
- 10 daysPublisher website ·
- Submission to first decision
- 10 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 2,600 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers2, by deadline
Publisher websiteWhat to prepare8 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 3–8
- Manuscript length
- ≤ 3,000 words
- Reference style
- Numbered, in order of citation
- Templates
- Word
- Suggested reviewers
- Optional
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted13
- commentary(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- editorial(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- letter to editorA Letter to Editor is usually an open post-publication review of a paper from its readers, often critical of some aspect of a published paper. Controversial pap…Length not stated
- meta-analysis(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- mini review(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- mini review/reviewA Mini Review/Review article should provide readers with an in-depth understanding of a field by summarizing existing literature, and highlight key gaps and cha…Length not stated
- opinion(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- original article(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- original research article(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- perspective(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- review article(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- systematic review(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
- technical note(1) Figures and TablesFigures and tables should be used judiciously, presented clearly, and designed to strengthen the presentation of evidence and the interpre…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Trial registration / reporting guidelines
- AI use 2.3.3.4 AI and AI-assisted tools Statement
AI-generated content must adhere to ethical standards; authors verify accuracy Model summary
Authors should disclose in their manuscript the use of AI and AI-assisted technologies. Declaring the use of these technologies supports transparency and trust between authors, readers, reviewers, editors and contributors and facilitates compliance with the terms of use of the relevant tool or technology.If the manuscript does not involve this issue, state "Not applicable." in this section.
Source ↗Publisher website ·- Authorship 4. Authorship
Authorship credit of OAE journals should be solely based on substantial contributions to a published study, as specified in the following four criteria:1. Substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work;2. Drafting the work or revising it critically for important intellectual content;3. Final approval of the ve…
Source ↗Publisher website ·- Conflicts of interest 2.3.3.6 Conflicts of Interest
Authors must declare any potential conflicts of interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. If there are no conflicts of interest, please state "All authors declared that there are no conflicts of interest." in this section. Some authors may be bound by confidentiality agreements. In such cases, in place of itemiz…
Source ↗Publisher website ·- Data availability 2.3.3.3 Availability of Data and Materials
In order to maintain the integrity, transparency and reproducibility of research records, authors should include this section in their manuscripts, detailing where the data supporting their findings can be found. Data can be deposited into data repositories or published as supplementary information in the journal. Authors who cannot share their data should state that the data will not be shared an…
Source ↗Publisher website ·- Publication ethics 2.3.3.7 Ethical Approval and Consent to Participate
Member of COPE, adheres to Code of Conduct and Best Practice Guidelines Model summary
Research involving human subjects, human material or human data must be performed in accordance with the Declaration of Helsinki and approved by an appropriate ethics committee. An informed consent to participate in the study should also be obtained from participants, or their parents or legal guardians for children under 16. A statement detailing the name of the ethics committee (including the re…
Source ↗Publisher website ·- License & copyright 1.2 Open Access and Copyright
The journal adopts Gold Open Access publishing model since its establishment and has been distributing contents under Attribution 4.0 International License since October 2017, whereas Attribution-NonCommercial-ShareAlike 3.0 Unported had been adopted by then. Copyright is retained by authors. Please make sure that you are well aware of these policies.
Source ↗Publisher website ·- Open access 1.2 Open Access and Copyright
Gold Open Access, CC BY 4.0 since Oct 2017, authors retain copyright Model summary
The journal adopts Gold Open Access publishing model since its establishment and has been distributing contents under Attribution 4.0 International License since October 2017, whereas Attribution-NonCommercial-ShareAlike 3.0 Unported had been adopted by then. Copyright is retained by authors. Please make sure that you are well aware of these policies.
Source ↗Publisher website ·- Peer review 7.3 AI Use in Peer Review
Confidentiality requirements: Reviewers must not upload manuscripts/materials to AI platforms, as this: 1. Violates OAE’s confidentiality policies2. Risks intellectual property infringement3. May compromise personal data in identifiable content Review integrity standards: Peer review must remain human-driven – AI tools cannot replace critical scholarly judgment.Reviewers must not use AI for manusc…
Source ↗Publisher website ·- Trial registration / reporting guidelines 3.1.5 Trial Registration
OAE requires all authors to register all relevant clinical trials that are reported in manuscripts submitted. OAE follows the World Health Organization (WHO)'s definition of clinical trials: "A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. Interventions i…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- OAE Publishing Inc.
- ISSN
- 2394-5079
- Electronic ISSN
- 2454-2520
- Official links
- Journal homepage ↗OpenAlex
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Hepatoma Research
What CAS zone is Hepatoma Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Hepatoma Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Gastroenterology & Hepatology / Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Hepatoma Research?
The journal's website gives an impact factor of 1.8 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 3, h-index 26.
How long does peer review take at Hepatoma Research?
The publisher reports about 10 days (submission to first decision); first decisions include desk rejections. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Hepatoma Research?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 3–8; Manuscript length: ≤ 3,000 words; Reference style: Numbered, in order of citation; Templates: Word; Suggested reviewers: Optional; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Hepatoma Research based?
Of the 99 board members whose country the journal's board page names, 40 (about 40%) are in mainland China; the countries named most often are Mainland China (40), Italy (19) and United States (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Hepatoma Research?
According to LetPub and DOAJ records, Hepatoma Research is indexed in ESCI and Scopus.
Is Hepatoma Research open access, and what is the APC?
Hepatoma Research is a fully open-access journal. APC about USD 2,600.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .